1503-53-3

Usage

Purification Methods

Est Crystallise the acid from EtOH. [Robertson J Chem Soc 81 1482 1902, Beilstein 10 H 108, 10 II 64.]

InChI:InChI=1/C9H7BrO4/c1-5(11)14-8-3-2-6(10)4-7(8)9(12)13/h2-4H,1H3,(H,12,13)

Upstream product

• 89-55-4 5-bromosalicyclic acid 
• 108-24-7 acetic anhydride 
• 75-36-5 acetyl chloride 

Downstream Products

• 5485-91-6 2-acetoxy-5-bromo-benzoyl chloride 
• 1760-84-5 2-hydroxy-3-acetyl-5-bromobenzoic acid 
• 1175095-00-7 4-hydroxy-6-(4-methoxy-phenyl)-2-oxo-2H-chromene-3-carboxylic acid methyl ester 
• 2411-23-6 Anhydrid der 2-Acetoxy-5-brom-benzoesaeure 
• 1237519-45-7 C₃₂H₂₉NO₅ 
• 1237519-42-4 C₂₄H₂₂BrNO₄ 
• 1237515-10-4 2-(5-(6-aminopyridin-2-yl)-2-hydroxybenzamido)-4-phenylbenzoic acid 
• 1237519-49-1 tert-butyl 2-(5-(6-aminopyridin-2-yl)-2-hydroxybenzamido)-4-phenylbenzoate 
• 1237515-09-1 tert-butyl 2-(2-acetoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamido)-4-phenylbenzoate 
• 1237514-87-2 tert-butyl 2-(2-acetoxy-5-bromobenzamido)-4-phenylbenzoate 
• 1237514-96-3 methyl 2-(2-acetoxy-5-bromobenzamido)-4-phenylbenzoate 
• 1237515-04-6 2-(2-hydroxy-5-phenylbenzamido)-4-phenylbenzoic acid 
• 1237519-46-8 tert-butyl 2-(2-hydroxy-5-phenylbenzamido)-4-phenylbenzoate 
• 1237515-00-2 2-(5-bromo-2-hydroxybenzamido)-4-phenylbenzoic acid 

Relevant academic research and scientific papers

COMPOUNDS AND USES THEREOF

The present invention relates to compositions and methods for the treatment of HA01 -associated disorders, such as primary hyperoxaluria 1.

Synthesis and antioxidant activities of berberine 9-: O -benzoic acid derivatives

Although berberine (BBR) shows antioxidant activity, its activity is limited. We synthesized 9-O-benzoic acid berberine derivatives, and their antioxidant activities were screened via ABTS, DPPH, HOSC and FRAP assays. The para-position was modified with halogen elements on the benzoic acid ring, which led to an enhanced antioxidant activity and the substituent on the ortho-position was found to be better than the meta-position. Compounds 8p, 8c, 8d, 8i, 8j, 8l, and especially 8p showed significantly higher antioxidant activities, which could be attributed to the electronic donating groups. All the berberine derivatives possessed proper lipophilicities. In conclusion, compound 8p is a promising antioxidant candidate with remarkable elevated antioxidant activity and moderate lipophilicity.

Synthesis, biological evaluation and 3D-QSAR studies of 3-keto salicylic acid chalcones and related amides as novel HIV-1 integrase inhibitors

HIV-1 integrase is one of the three most important enzymes required for viral replication and is therefore an attractive target for anti retroviral therapy. We herein report the design and synthesis of 3-keto salicylic acid chalcone derivatives as novel HIV-1 integrase inhibitors. The most active compound, 5-bromo-2-hydroxy-3-[3-(2,3,6-trichlorophenyl)acryloyl]benzoic acid (25) was selectively active against integrase strand transfer, with an IC 50 of 3.7 μM. While most of the compounds exhibited strand transfer selectivity, a few were nonselective, such as 5-bromo-3-[3-(4- bromophenyl)acryloyl]-2-hydroxybenzoic acid (15), which was active against both 3′-processing and strand transfer with IC50 values of 11 ± 4 and 5 ± 2 μM, respectively. The compounds also inhibited HIV replication with potencies comparable with their integrase inhibitory potencies. Thus, 5-bromo-2-hydroxy-3-[3-(2,3,6-trichlorophenyl)acryloyl]benzoic acid (25) and 5-bromo-3-[3-(4-bromophenyl)acryloyl]-2-hydroxybenzoic acid (15) inhibited HIV-1 replication with EC50 values of 7.3 and 8.7 μM, respectively. A PHASE pharmacophore hypothesis was developed and validated by 3D-QSAR, which gave a predictive r2 of 0.57 for an external test set of ten compounds. Phamacophore derived molecular alignments were used for CoMFA and CoMSIA 3D-QSAR modeling. CoMSIA afforded the best model with q2 and r2 values of 0.54 and 0.94, respectively. This model predicted all the ten compounds of the test set within 0.56 log units of the actual pIC50 values; and can be used to guide the rational design of more potent novel 3-keto salicylic acid integrase inhibitors.

Influence of impurities on the crystallisation of 5-X-aspirin and 5-X-aspirin anhydride polymorphs (X = Cl, Br, Me)

Crystallisation of 5-X-aspirin (X = Cl, Br) by ambient evaporation from organic solvents commonly yields a mixture of polymorphs I and II for X = Cl, but only polymorph I for X = Br. Addition of 5-X-aspirin anhydride (5-20 mol %) leads to sole production

CHROMENONE ANALOGS AS SIRTUIN MODULATORS

Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for e

CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS

The present invention relates to novel compounds of formula (I), methods, and compositions capable of decreasing HIF hydroxylase activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).

ARYL AND HETEROARYL COMPOUNDS AND METHODS TO MODULATE COAGULATION

This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as antagonists, or more preferably, partial antagonist of factor IX and thus, may be used to inhibit the intrinsic pathway of blood coagulation. The compounds are useful in a variety of applications including the management, treatment and/or control of diseases caused in part by the intrinsic clotting pathway utilizing factor IX. Such diseases or disease states include stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures, long periods of confinement, and acquired or inherited pro-coagulant states.

4-Aminoarylguanidine and 4-aminobenzamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors

The structure-based design of potent and selective urokinase-type plasminogen activator (uPA) inhibitors with 4-aminoarylamidine or 4-aminoarylguanidine S1 binding groups, is described.

A highly practical route to 2-methylchromones from 2-acetoxybenzoic acids

2-Methylchromones were accessed via a keto ester condensation on 2-acetoxybenzoyl chloride, followed by cyclization and decarboxylation. No column chromatography was required in the process.

Flavone derivative and medicine comprising the same

This invention relates to a flavone derivative represented by the formula (1) or a salt thereof, and also to a medicine containing the same. wherein A represents H, halogen, phenyl, naphthyl, a group of the formula (2) in which X is H or halogen, B is -CH